Logo

EraCal Therapeutics Collaborates with Novo Nordisk to Develop and Commercialize its Small Molecule Program

Share this
Novo Nordisk

EraCal Therapeutics Collaborates with Novo Nordisk to Develop and Commercialize its Small Molecule Program

Shots:

  • EraCal Therapeutics and Novo Nordisk have signed a collaboration and license agreement for the development and commercialization of EraCal’s oral, small-molecule program
  • Under the terms of the agreement, EraCal will obtain upfront, development, and commercial milestones of up to $256.29M (€235M) along with royalties on sales while Novo Nordisk receives the exclusive development and commercialization rights of the program
  • The discovery of the program has been carried out with EraCal’s platform technology which aims to target a novel mechanism of action controlling appetite and body weight to treat obesity

Ref: EraCal Therapeutics | Image: Novo Nordisk

Related News:- Dewpoint Therapeutics Collaborates with Evotec to Accelerate its Oncology Pipeline

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions